Reconceptualization of translocator protein as a biomarker of neuroinflammation in psychiatry
A great deal of interest in psychiatric research is currently centered upon the pathogenic role of inflammatory processes. Positron emission tomography (PET) using radiolabeled ligands selective for the 18 kDa translocator protein (TSPO) has become the most widely used technique to assess putative n...
Gespeichert in:
Veröffentlicht in: | Molecular psychiatry 2018-01, Vol.23 (1), p.36-47 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 47 |
---|---|
container_issue | 1 |
container_start_page | 36 |
container_title | Molecular psychiatry |
container_volume | 23 |
creator | Notter, T Coughlin, J M Sawa, A Meyer, U |
description | A great deal of interest in psychiatric research is currently centered upon the pathogenic role of inflammatory processes. Positron emission tomography (PET) using radiolabeled ligands selective for the 18 kDa translocator protein (TSPO) has become the most widely used technique to assess putative neuroimmune abnormalities
in vivo
. Originally used to detect discrete neurotoxic damages, TSPO has generally turned into a biomarker of ‘neuroinflammation’ or ‘microglial activation’. Psychiatric research has mostly accepted these denotations of TSPO, even if they may be inadequate and misleading under many pathological conditions. A reliable and neurobiologically meaningful diagnosis of ‘neuroinflammation’ or ‘microglial activation’ is unlikely to be achieved by the sole use of TSPO PET imaging. It is also very likely that the pathological meanings of altered TSPO binding or expression are disease-specific, and therefore, not easily generalizable across different neuropathologies or inflammatory conditions. This difficulty is intricately linked to the varying (and still ill-defined) physiological functions and cellular expression patterns of TSPO in health and disease. While altered TSPO binding or expression may indeed mirror ongoing neuroinflammatory processes in some cases, it may reflect other pathophysiological processes such as abnormalities in cell metabolism, energy production and oxidative stress in others. Hence, the increasing popularity of TSPO PET imaging has paradoxically introduced substantial uncertainty regarding the nature and meaning of neuroinflammatory processes and microglial activation in psychiatry, and likely in other neuropathological conditions as well. The ambiguity of conceiving TSPO simply as a biomarker of ‘neuroinflammation’ or ‘microglial activation’ calls for alternative interpretations and complimentary approaches. Without the latter, the ongoing scientific efforts and excitement surrounding the role of the neuroimmune system in psychiatry may not turn into therapeutic hope for affected individuals. |
doi_str_mv | 10.1038/mp.2017.232 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_1983672296</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A521121949</galeid><sourcerecordid>A521121949</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-dcbed73db3792519b4cc0842c18797247dc4f66697b421bba954d390111ed9d63</originalsourceid><addsrcrecordid>eNptkc1LwzAYxoMobk5P3qXgUVubNG2a4xh-wUAQPUpIk3Rmtk1N0sP8683olAmSQ0Le3_N-PQCcwzSBaVbetH2CUkgSlKEDMIWYFHGek_IwvLOcxhiWeAJOnFun6TaYH4MJoigoMZmCt2clTCdU7wfe6C_utekiU0fe8s41RnBvbNRb45XuIu4iHlXatNx-KLvFOjVYo7u64W07agPWu41419zbzSk4qnnj1NnunoHXu9uXxUO8fLp_XMyXscAl8bEUlZIkk1VGKMohrbAQaYmRgCWhBGEiBa6LoqCkwghWFac5lhlNIYRKUllkM3A55g2dfg7KebY2g-1CSQZpmRUEIbpHrXijWOjahClFq51g8xxBiCDFNFDJP1Q4UrU67ErVOvz_EVyNAmGNc1bVrLc6rGjDYMq2DrG2Z1uHWHAo0Be7VoeqVfKX_bEkANcj4EKoWym7N8s_-b4BzIyZtg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1983672296</pqid></control><display><type>article</type><title>Reconceptualization of translocator protein as a biomarker of neuroinflammation in psychiatry</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Notter, T ; Coughlin, J M ; Sawa, A ; Meyer, U</creator><creatorcontrib>Notter, T ; Coughlin, J M ; Sawa, A ; Meyer, U</creatorcontrib><description>A great deal of interest in psychiatric research is currently centered upon the pathogenic role of inflammatory processes. Positron emission tomography (PET) using radiolabeled ligands selective for the 18 kDa translocator protein (TSPO) has become the most widely used technique to assess putative neuroimmune abnormalities
in vivo
. Originally used to detect discrete neurotoxic damages, TSPO has generally turned into a biomarker of ‘neuroinflammation’ or ‘microglial activation’. Psychiatric research has mostly accepted these denotations of TSPO, even if they may be inadequate and misleading under many pathological conditions. A reliable and neurobiologically meaningful diagnosis of ‘neuroinflammation’ or ‘microglial activation’ is unlikely to be achieved by the sole use of TSPO PET imaging. It is also very likely that the pathological meanings of altered TSPO binding or expression are disease-specific, and therefore, not easily generalizable across different neuropathologies or inflammatory conditions. This difficulty is intricately linked to the varying (and still ill-defined) physiological functions and cellular expression patterns of TSPO in health and disease. While altered TSPO binding or expression may indeed mirror ongoing neuroinflammatory processes in some cases, it may reflect other pathophysiological processes such as abnormalities in cell metabolism, energy production and oxidative stress in others. Hence, the increasing popularity of TSPO PET imaging has paradoxically introduced substantial uncertainty regarding the nature and meaning of neuroinflammatory processes and microglial activation in psychiatry, and likely in other neuropathological conditions as well. The ambiguity of conceiving TSPO simply as a biomarker of ‘neuroinflammation’ or ‘microglial activation’ calls for alternative interpretations and complimentary approaches. Without the latter, the ongoing scientific efforts and excitement surrounding the role of the neuroimmune system in psychiatry may not turn into therapeutic hope for affected individuals.</description><identifier>ISSN: 1359-4184</identifier><identifier>EISSN: 1476-5578</identifier><identifier>DOI: 10.1038/mp.2017.232</identifier><identifier>PMID: 29203847</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13/21 ; 59/78 ; 631/378 ; 692/53/2421 ; 692/699/476/1799 ; Activation ; Animals ; Behavioral Sciences ; Bioindicators ; Biological markers ; Biological Psychology ; Biomarkers ; Biomarkers - metabolism ; Encephalitis - diagnostic imaging ; Encephalitis - etiology ; Encephalitis - metabolism ; Energy metabolism ; expert-review ; Humans ; Inflammation ; Medical imaging ; Medicine ; Medicine & Public Health ; Mental Disorders - complications ; Mental Disorders - diagnostic imaging ; Models, Molecular ; Neurons ; Neurosciences ; Neurotoxicity ; Oxidative metabolism ; Oxidative stress ; Pharmacotherapy ; Positron emission tomography ; Psychiatry ; Receptors, GABA - metabolism ; Tomography</subject><ispartof>Molecular psychiatry, 2018-01, Vol.23 (1), p.36-47</ispartof><rights>Macmillan Publishers Limited, part of Springer Nature. 2018</rights><rights>COPYRIGHT 2018 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jan 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-dcbed73db3792519b4cc0842c18797247dc4f66697b421bba954d390111ed9d63</citedby><cites>FETCH-LOGICAL-c487t-dcbed73db3792519b4cc0842c18797247dc4f66697b421bba954d390111ed9d63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/mp.2017.232$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/mp.2017.232$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29203847$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Notter, T</creatorcontrib><creatorcontrib>Coughlin, J M</creatorcontrib><creatorcontrib>Sawa, A</creatorcontrib><creatorcontrib>Meyer, U</creatorcontrib><title>Reconceptualization of translocator protein as a biomarker of neuroinflammation in psychiatry</title><title>Molecular psychiatry</title><addtitle>Mol Psychiatry</addtitle><addtitle>Mol Psychiatry</addtitle><description>A great deal of interest in psychiatric research is currently centered upon the pathogenic role of inflammatory processes. Positron emission tomography (PET) using radiolabeled ligands selective for the 18 kDa translocator protein (TSPO) has become the most widely used technique to assess putative neuroimmune abnormalities
in vivo
. Originally used to detect discrete neurotoxic damages, TSPO has generally turned into a biomarker of ‘neuroinflammation’ or ‘microglial activation’. Psychiatric research has mostly accepted these denotations of TSPO, even if they may be inadequate and misleading under many pathological conditions. A reliable and neurobiologically meaningful diagnosis of ‘neuroinflammation’ or ‘microglial activation’ is unlikely to be achieved by the sole use of TSPO PET imaging. It is also very likely that the pathological meanings of altered TSPO binding or expression are disease-specific, and therefore, not easily generalizable across different neuropathologies or inflammatory conditions. This difficulty is intricately linked to the varying (and still ill-defined) physiological functions and cellular expression patterns of TSPO in health and disease. While altered TSPO binding or expression may indeed mirror ongoing neuroinflammatory processes in some cases, it may reflect other pathophysiological processes such as abnormalities in cell metabolism, energy production and oxidative stress in others. Hence, the increasing popularity of TSPO PET imaging has paradoxically introduced substantial uncertainty regarding the nature and meaning of neuroinflammatory processes and microglial activation in psychiatry, and likely in other neuropathological conditions as well. The ambiguity of conceiving TSPO simply as a biomarker of ‘neuroinflammation’ or ‘microglial activation’ calls for alternative interpretations and complimentary approaches. Without the latter, the ongoing scientific efforts and excitement surrounding the role of the neuroimmune system in psychiatry may not turn into therapeutic hope for affected individuals.</description><subject>13/21</subject><subject>59/78</subject><subject>631/378</subject><subject>692/53/2421</subject><subject>692/699/476/1799</subject><subject>Activation</subject><subject>Animals</subject><subject>Behavioral Sciences</subject><subject>Bioindicators</subject><subject>Biological markers</subject><subject>Biological Psychology</subject><subject>Biomarkers</subject><subject>Biomarkers - metabolism</subject><subject>Encephalitis - diagnostic imaging</subject><subject>Encephalitis - etiology</subject><subject>Encephalitis - metabolism</subject><subject>Energy metabolism</subject><subject>expert-review</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mental Disorders - complications</subject><subject>Mental Disorders - diagnostic imaging</subject><subject>Models, Molecular</subject><subject>Neurons</subject><subject>Neurosciences</subject><subject>Neurotoxicity</subject><subject>Oxidative metabolism</subject><subject>Oxidative stress</subject><subject>Pharmacotherapy</subject><subject>Positron emission tomography</subject><subject>Psychiatry</subject><subject>Receptors, GABA - metabolism</subject><subject>Tomography</subject><issn>1359-4184</issn><issn>1476-5578</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNptkc1LwzAYxoMobk5P3qXgUVubNG2a4xh-wUAQPUpIk3Rmtk1N0sP8683olAmSQ0Le3_N-PQCcwzSBaVbetH2CUkgSlKEDMIWYFHGek_IwvLOcxhiWeAJOnFun6TaYH4MJoigoMZmCt2clTCdU7wfe6C_utekiU0fe8s41RnBvbNRb45XuIu4iHlXatNx-KLvFOjVYo7u64W07agPWu41419zbzSk4qnnj1NnunoHXu9uXxUO8fLp_XMyXscAl8bEUlZIkk1VGKMohrbAQaYmRgCWhBGEiBa6LoqCkwghWFac5lhlNIYRKUllkM3A55g2dfg7KebY2g-1CSQZpmRUEIbpHrXijWOjahClFq51g8xxBiCDFNFDJP1Q4UrU67ErVOvz_EVyNAmGNc1bVrLc6rGjDYMq2DrG2Z1uHWHAo0Be7VoeqVfKX_bEkANcj4EKoWym7N8s_-b4BzIyZtg</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Notter, T</creator><creator>Coughlin, J M</creator><creator>Sawa, A</creator><creator>Meyer, U</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20180101</creationdate><title>Reconceptualization of translocator protein as a biomarker of neuroinflammation in psychiatry</title><author>Notter, T ; Coughlin, J M ; Sawa, A ; Meyer, U</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-dcbed73db3792519b4cc0842c18797247dc4f66697b421bba954d390111ed9d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>13/21</topic><topic>59/78</topic><topic>631/378</topic><topic>692/53/2421</topic><topic>692/699/476/1799</topic><topic>Activation</topic><topic>Animals</topic><topic>Behavioral Sciences</topic><topic>Bioindicators</topic><topic>Biological markers</topic><topic>Biological Psychology</topic><topic>Biomarkers</topic><topic>Biomarkers - metabolism</topic><topic>Encephalitis - diagnostic imaging</topic><topic>Encephalitis - etiology</topic><topic>Encephalitis - metabolism</topic><topic>Energy metabolism</topic><topic>expert-review</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mental Disorders - complications</topic><topic>Mental Disorders - diagnostic imaging</topic><topic>Models, Molecular</topic><topic>Neurons</topic><topic>Neurosciences</topic><topic>Neurotoxicity</topic><topic>Oxidative metabolism</topic><topic>Oxidative stress</topic><topic>Pharmacotherapy</topic><topic>Positron emission tomography</topic><topic>Psychiatry</topic><topic>Receptors, GABA - metabolism</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Notter, T</creatorcontrib><creatorcontrib>Coughlin, J M</creatorcontrib><creatorcontrib>Sawa, A</creatorcontrib><creatorcontrib>Meyer, U</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Molecular psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Notter, T</au><au>Coughlin, J M</au><au>Sawa, A</au><au>Meyer, U</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reconceptualization of translocator protein as a biomarker of neuroinflammation in psychiatry</atitle><jtitle>Molecular psychiatry</jtitle><stitle>Mol Psychiatry</stitle><addtitle>Mol Psychiatry</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>23</volume><issue>1</issue><spage>36</spage><epage>47</epage><pages>36-47</pages><issn>1359-4184</issn><eissn>1476-5578</eissn><abstract>A great deal of interest in psychiatric research is currently centered upon the pathogenic role of inflammatory processes. Positron emission tomography (PET) using radiolabeled ligands selective for the 18 kDa translocator protein (TSPO) has become the most widely used technique to assess putative neuroimmune abnormalities
in vivo
. Originally used to detect discrete neurotoxic damages, TSPO has generally turned into a biomarker of ‘neuroinflammation’ or ‘microglial activation’. Psychiatric research has mostly accepted these denotations of TSPO, even if they may be inadequate and misleading under many pathological conditions. A reliable and neurobiologically meaningful diagnosis of ‘neuroinflammation’ or ‘microglial activation’ is unlikely to be achieved by the sole use of TSPO PET imaging. It is also very likely that the pathological meanings of altered TSPO binding or expression are disease-specific, and therefore, not easily generalizable across different neuropathologies or inflammatory conditions. This difficulty is intricately linked to the varying (and still ill-defined) physiological functions and cellular expression patterns of TSPO in health and disease. While altered TSPO binding or expression may indeed mirror ongoing neuroinflammatory processes in some cases, it may reflect other pathophysiological processes such as abnormalities in cell metabolism, energy production and oxidative stress in others. Hence, the increasing popularity of TSPO PET imaging has paradoxically introduced substantial uncertainty regarding the nature and meaning of neuroinflammatory processes and microglial activation in psychiatry, and likely in other neuropathological conditions as well. The ambiguity of conceiving TSPO simply as a biomarker of ‘neuroinflammation’ or ‘microglial activation’ calls for alternative interpretations and complimentary approaches. Without the latter, the ongoing scientific efforts and excitement surrounding the role of the neuroimmune system in psychiatry may not turn into therapeutic hope for affected individuals.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>29203847</pmid><doi>10.1038/mp.2017.232</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1359-4184 |
ispartof | Molecular psychiatry, 2018-01, Vol.23 (1), p.36-47 |
issn | 1359-4184 1476-5578 |
language | eng |
recordid | cdi_proquest_journals_1983672296 |
source | MEDLINE; SpringerLink Journals |
subjects | 13/21 59/78 631/378 692/53/2421 692/699/476/1799 Activation Animals Behavioral Sciences Bioindicators Biological markers Biological Psychology Biomarkers Biomarkers - metabolism Encephalitis - diagnostic imaging Encephalitis - etiology Encephalitis - metabolism Energy metabolism expert-review Humans Inflammation Medical imaging Medicine Medicine & Public Health Mental Disorders - complications Mental Disorders - diagnostic imaging Models, Molecular Neurons Neurosciences Neurotoxicity Oxidative metabolism Oxidative stress Pharmacotherapy Positron emission tomography Psychiatry Receptors, GABA - metabolism Tomography |
title | Reconceptualization of translocator protein as a biomarker of neuroinflammation in psychiatry |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T17%3A12%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reconceptualization%20of%20translocator%20protein%20as%20a%20biomarker%20of%20neuroinflammation%20in%20psychiatry&rft.jtitle=Molecular%20psychiatry&rft.au=Notter,%20T&rft.date=2018-01-01&rft.volume=23&rft.issue=1&rft.spage=36&rft.epage=47&rft.pages=36-47&rft.issn=1359-4184&rft.eissn=1476-5578&rft_id=info:doi/10.1038/mp.2017.232&rft_dat=%3Cgale_proqu%3EA521121949%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1983672296&rft_id=info:pmid/29203847&rft_galeid=A521121949&rfr_iscdi=true |